GO
Loading...

GlaxoSmithKline PLC

More

  • For big business in China he's a headache, part of a small but fast-growing industry built around exposing corporate wrongdoing.

  • GlaxoSmithKline discloses new bribery inquiries Wednesday, 16 Apr 2014 | 12:25 PM ET

    NEW YORK— British drugmaker GlaxoSmithKline is looking into allegations of bribery within its operations in Jordan and Lebanon. On Monday the BBC reported that GlaxoSmithKline PLC is facing a bribery investigation in Poland, where a sales representative allegedly paid doctors to prescribe the company's asthma drug Seretide.

  • FDA approves injectable diabetes drug from Glaxo Tuesday, 15 Apr 2014 | 3:08 PM ET

    WASHINGTON— The Food and Drug Administration said Tuesday it approved a new injectable drug from GlaxoSmithKline plc for adults with Type 2 diabetes. The FDA said it approved the new drug based on eight trials including more than 2,000 patients.

  • April 15- The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise. However, it is unknown whether Tanzeum causes thyroid C-cell tumors, the FDA said on its website.

  • FDA approves GSK's Tanzeum to treat type 2 diabetes Tuesday, 15 Apr 2014 | 10:35 AM ET

    April 15- The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise. However, it is unknown whether Tanzeum causes thyroid C-cell tumors, the FDA said on its website.

  • Report: Glaxo bribed doctors in Poland Monday, 14 Apr 2014 | 9:00 AM ET

    LONDON— The BBC reports that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to prescribe medicines in Poland. The British drug company faces corruption probes in China and Iraq.

  • *Allegations follow corruption accusations in China, Iraq. LONDON/ WARSAW, April 14- GlaxoSmithKline is facing a criminal investigation in Poland for allegedly bribing doctors to promote its lung drug Seretide, adding to problems for a company already accused of corruption in China and Iraq.

  • April 14- Within hours of the U.S. government's unprecedented release last week of a trove of Medicare billing data, a small fraternity of lawyers who specialize in representing whistleblowers in healthcare fraud cases began to mobilize.

  • Many 'Obamacare' critics accepted its subsidies Tuesday, 8 Apr 2014 | 4:07 PM ET

    Among the corporations is a familiar Democratic nemesis, Koch Industries, the giant conglomerate headed by the billionaire brothers Charles and David Koch. In a Senate chamber speech, Reid noted that Koch Industries benefited from a temporary provision of the health care law.

  • Teva launches generic version of fish oil drug Tuesday, 8 Apr 2014 | 10:47 AM ET

    NEW YORK— Teva Pharmaceutical Industries said Tuesday it is now selling a generic version of the heart medication Lovaza, which is used to treat high triglyceride levels.

  • GSK launches probe into Iraq bribery claims Monday, 7 Apr 2014 | 11:41 AM ET

    LONDON— GlaxoSmithKline said Monday it has launched an investigation into allegations it bribed doctors in Iraq, as the pharmaceuticals giant remains embroiled in a major corruption scandal in China.

  • LONDON, April 4- GlaxoSmithKline, facing allegations of bribery in China, has dismissed some employees in the country over failure to comply with expenses rules, a person familiar with the situation said on Friday.

  • April 3- Amgen Inc said it would end an agreement with GlaxoSmithKline Plc for the marketing of its osteoporosis drug in some regions outside the United States. Amgen said it would take over the marketing of the drug, sold under the brand name Prolia, in most areas under the agreement, including the European Union, Switzerland, Norway, Russia and Mexico, by Dec. 31.

  • April 3- Amgen Inc said it was ending an agreement with GlaxoSmithKline Plc, under which the British company marketed Amgen's postmenopausal osteoporosis drug in some regions outside the United States.

  • April 2- Bill Gates, the World Bank and other donors are stepping up efforts to fight neglected tropical diseases in Africa and other low-income regions with a $240 million injection of new funding. The new collaboration includes $50 million from the Bill& Melinda Gates Foundation and $50 million from the Children's Investment Fund Foundation.

  • BUSINESS-NEWS-SCHEDULE AT 1230 GMT / 8.30 AM ET Wednesday, 2 Apr 2014 | 8:55 AM ET

    PARIS- Arnaud Montebourg, a fierce critic of budget austerity, is named French economy minister in a reshuffled government that President Francois Hollande has charged with halting France's economic decline. EU regulators fine Goldman Sachs, Prysmian for cable cartel.

  • Early movers: GM, WFC, TWC, CHTR & more Wednesday, 2 Apr 2014 | 7:40 AM ET

    Some of the names on the move ahead of the open.

  • LONDON, April 2- GlaxoSmithKline Plc has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit.

  • April 1- The U.S. Food and Drug Administration found that a drug ingredient manufactured at a GlaxoSmithKline Plc plant in Ireland was contaminated and said the company did not take sufficient action to resolve the problems.

  • FDA said GSK did not fully investigate a list of objectional conditions the regulator sent after its inspection of the manufacturing plant at Cork, Ireland in October. The FDA said its investigator found that a certain drug ingredient, the name of which was not disclosed, was contaminated with material from the plant's pharmaceutical waste tank.

Most Popular Video

Thursday, 17 Apr 2014 | 4:13 PM ET

Dissecting today's market activity and the current state of financials, with Yra Harris, Praxis Trading partner; Larry Glazer, Mayflower Advisors; CNBC contributor Carol Roth; "Fast Money" Guy Adami and CNBC's Kate Kelly.

Thursday, 17 Apr 2014 | 5:46 PM ET

CNBC voice over talent Jim Birdsall shares the top 5 sayings from traders on "Fast Money" over the years.

Thursday, 17 Apr 2014 | 6:40 PM ET

Mad Money's Jim Cramer reflects on CNBC's evolution over the past 25 years.